Comparative genomic hybridization (CGH) was developed to identify pathogenic DNA copy-number changes (e.g., duplications, deletions) on a genome-wide scale, and to map these changes to genomic ...
Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma Genomic losses were ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full text component.
Scott W. Stuart, MD, MS; Casey H. King, BA; G. Shashidar Pai, MD Such observations emphasize the importance of clarifying the origin of a genetic variation by studying the parents for comparison. The ...
CHICAGO --The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the ...
Microarrays have been a mainstay of the scientific research community for nearly a decade but given the more stringent demands for accuracy and reliability, have not been as closely embraced in the ...
Agilent Technologies Inc. and Cogenics, a division of Clinical Data, Inc. have announced that Cogenics has been recertified, for the third year, as a Certified Microarray Service Provider for Agilent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results